Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data at the 2024 American Society of Clinical...

Related Keywords

Texas ,United States ,San Carlos ,California ,American ,Mridula George ,Ryoichi Naito ,Rebecca Hassoun ,Aziz Zaanan ,Sarah Lee ,Sherene Loi ,Marla Lipsyc Sharf ,Yoshiaki Nakamura ,Glenn Hanna ,Adanma Ayanambakkam ,Eric Lander ,Michael Lapelusa ,Nasdaq ,Clinical Laboratory Improvement Amendments ,American Society Of Clinical Oncology ,Natera Inc ,Clinical Oncology ,Annual Meeting ,Breast Cancer ,Testicular Cancer ,Prognostic Biomarker ,Detect Minimal Residual Disease ,Urothelial Cancer ,Esophageal Cancer ,Recurrence Free Survival ,Resected Stage ,Exploratory Analysis ,Neck Squamous Cell Carcinoma ,Yasushi Goto ,Lung Cancer ,